Related Experiment Video
Updated: Sep 13, 2025
Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
Clinical, Radiological and Pharmacokinetic Data of CT-P13 Subcutaneous in Individuals with Fistulizing Anoperineal
N Fathallah1,2, M Draullette3, J Kirchgesner3
1Department of Medical and Surgical Proctology, Hôpital Paris Saint-Joseph, 185, Rue Raymond Losserand, 75014, Paris, France. drnadia.fathallah@gmail.com.
Purpose:
The aim of this study was to evaluate the clinico-radiological remission rate in patients with fistulizing anoperineal lesions of Crohn's disease treated with CT-P13 SC, as well as pharmacokinetic data and treatment persistence rate.
Methods:
We included all consecutive patients seen in the dedicated proctology outpatient clinic between June 1st and July 15th, 2024, for fistulizing anoperineal lesions and treated for at least 3 months with CT-P13 SC. Clinical, radiological and pharmacokinetic data were collected.
Results:
Data from 39 patients were analyzed. The median duration of treatment was 16.1 months. Seventeen patients (43.6%) had initiated SC formulation upfront. The complete clinical remission rate was 74.4%, significantly higher in patients switched from IV to SC formulation. Among patients switched from IV to SC formulation, 86.5% maintained remission. In the overall study population, 89.7% were able to continue treatment, with intensified protocols in 61.5% of patients. The deep radiological remission rate was 61.5%. The median infliximab concentration was 22.7 µg/mL. Only the intensified administration protocol was significantly associated with higher infliximab concentrations. Immunosuppressants had no impact. The median infliximab concentration was higher in patients in remission (35.9 µg/mL vs 22.4 µg/mL), but without any significant difference.
Conclusion:
CT-P13 SC appears to be at least as effective as the IV formulation for fistulizing anoperineal lesions, and switching from IV to SC allows remission to be maintained in the vast majority of cases. Despite numerically higher infliximab concentrations in patients in remission, no significant difference could be identified. Trial registration number and date: Registration with the ethics committee on 11/14/2023.
More Related Videos
Related Concept Videos
01:27Imaging Studies III: Computed Tomography
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.